25 May 2013
Keywords: topotargets, initiates, ph, ii, savicol, trial, fap
Article | 20 February 2006
Denmark's TopoTarget A/S has commenced patient treatment in a pivotal Phase II study of Savicol, a histone deacetylase (HDAC) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
20 February 2006
24 May 2013
© 2013 thepharmaletter.com